News & events
Press Releases
On the 28th March 2022, OncoArendi changed its name to Molecure
Molecure Announces Details for Virtual R&D Day Webcast to be held on Wednesday 7th December 2022
5 December 2022
Molecure to begin clinical development of novel dual arginase inhibitor OATD-02 for the treatment of cancer after gaining permission to conduct first clinical trial in Poland
28 November 2022
Molecure Third Quarter 2022 Pipeline Highlights and Financial Results
31 October 2022
Molecure reports continued pipeline momentum for 6 months ended 30th June 2022
29 September 2022